Evogene - EVGN STOCK NEWS

Biomica, a subsidiary of Evogene Ltd. (NASDAQ: EVGN), has announced the advancement to large-scale production of its Live Bacterial Product candidate, BMC128. Following successful R&D, Biomica is preparing for first-in-man clinical trials in 2021. BMC128, a consortium of four bacterial strains, showed efficacy in enhancing immune-checkpoint inhibitors' effects during preclinical studies. The production will be managed by Biose Industrie, a GMP-certified manufacturer, marking a significant milestone for Biomica's immuno-oncology program.

Biomica Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), will present at the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, 2020. CEO Dr. Elran Haber will provide a business overview on September 16 at 12:30 PM EDT and engage in one-on-one meetings with institutional investors. Biomica focuses on microbiome-based therapeutics for antibiotic resistance, immuno-oncology, and gastrointestinal disorders, utilizing its Computational Predictive Biology platform. This participation aims to enhance investor engagement and showcase Biomica's innovations.

Evogene Ltd. (NASDAQ: EVGN) announced its participation in the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, 2020. Ofer Haviv, President & CEO, will present a company overview on September 16 at 12:00 PM (EDT) and will be available for one-on-one meetings with institutional investors. Evogene leverages its Computational Predictive Biology (CPB) platform to enhance product discovery across multiple life-science sectors, including human health and agriculture. This participation underscores its commitment to engaging with investors.

Biomica Ltd., a subsidiary of Evogene (NASDAQ: EVGN), announced positive pre-clinical in-vivo results for its immuno-oncology program. The study reported that BMC128, a combination of four bacterial strains, significantly improved anti-tumor activity in mice when combined with immune checkpoint inhibitors (ICI). These results suggest that the gut microbiome enhances the efficacy of cancer therapies. Biomica is preparing for first-in-man clinical trials in 2021, following additional pre-clinical studies.

Evogene Ltd. (NASDAQ: EVGN) has entered into a definitive agreement for a registered direct offering of ordinary shares at $1.70 each, totaling $10 million. ARK Investment Management will contribute $7 million, while Alpha Capital Anstalt will invest $3 million. The funds will be used to enhance product pipelines, expand their computational biology platform, and for general corporate purposes. The offering is expected to close by September 3, 2020, pending customary conditions. This offering follows a shelf registration statement declared effective by the SEC on August 10, 2020.

Evogene Ltd. (NASDAQ: EVGN) announced its participation in the LD 500 investor conference on September 2, 2020, at 9:40 AM ET. CEO Ofer Haviv will present to a live audience, highlighting Evogene's innovations in computational biology aimed at enhancing life-science product development across agriculture and health sectors. The LD 500, which runs from September 1-4, is fully virtual, allowing broad accessibility for investors. Interested parties can register online to participate in the conference and meet the CEO.

Evogene Ltd. (NASDAQ: EVGN) reported its Q2 2020 financial results, highlighting a cash position of approximately $38.1 million and revenues of $0.3 million, up from $0.2 million YoY. R&D expenses rose to $3.9 million, compared to $3.5 million in Q2 2019. Despite the COVID-19 challenges, the company aims to advance its technology solutions in agriculture and human health, with key projects in herbicides and microbiome-based therapeutics. Operating loss increased to $5.2 million from $4.7 million in the previous year, while the net loss reached approximately $4.8 million, compared to $4.1 million YoY.

Evogene Ltd. (NASDAQ: EVGN) announced that President and CEO Ofer Haviv will present at the Jefferies Virtual 2020 Industrials Conference on August 6, 2020, at 8:00 am EST. The presentation will highlight the company's innovative Computational Predictive Biology (CPB) platform, focusing on ag-chemicals and ag-biologicals. Investors interested in a meeting can contact Evogene's Investor Relations team. Evogene is dedicated to enhancing life-science product development through its unique technology and aims to address various market segments, including agriculture and human health.

Evogene Ltd. (NASDAQ: EVGN) will release its second-quarter 2020 financial results on August 5, 2020. The company's management will discuss these results in a conference call at 09:00 AM ET and 16:00 Israel time. The call can be accessed via telephone or live webcast on their website. Evogene focuses on computational biology to develop life-science products and employs its Computational Predictive Biology platform across various sectors including human health and agriculture.